{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:07:39Z","timestamp":1791846459864,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105088","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T23:35:22Z","timestamp":1765668922000},"page":"105088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Sequential use of targeted radioligand therapies in metastatic castration-resistant prostate cancer: A case report and systematic review"],"prefix":"10.1016","volume":"218","author":[{"given":"Hatice","family":"B\u00f6lek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Soydal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yeked\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye \u00d6zlem","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":false,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105088_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105088_bib2","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1007\/s00259-021-05383-3","article-title":"The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [(177)Lu]Lu-PSMA-617: a WARMTH multicentre study","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2025.105088_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","article-title":"Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177 Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"33","key":"10.1016\/j.critrevonc.2025.105088_bib4","doi-asserted-by":"crossref","first-page":"55567","DOI":"10.18632\/oncotarget.15698","article-title":"Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105088_bib5","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2967\/jnumed.123.265546","article-title":"Clinical experience with [(225)Ac]Ac-PSMA treatment in patients with [(177)Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer","volume":"64","author":"Alan-Selcuk","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105088_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu] Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105088_bib7","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s00259-023-06340-y","article-title":"Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study","volume":"50","author":"Ballal","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105088_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030557","article-title":"Safety and Efficacy of (177)Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing (223)Radium-Dichloride","volume":"14","author":"Baumgarten","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105088_bib9","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105088_bib10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"9747","key":"10.1016\/j.critrevonc.2025.105088_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105088_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105088_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105088_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","author":"Garje","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105088_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102260","article-title":"Safety and efficacy of 177Lu-PSMA therapy following 223Radium treatment: a retrospective multinational real-world analysis","volume":"23","author":"Giannini","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"issue":"10276","key":"10.1016\/j.critrevonc.2025.105088_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105088_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105088_bib18","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105088_bib19","doi-asserted-by":"crossref","unstructured":"Kassis A.I., editor Therapeutic radionuclides: biophysical and radiobiologic principles. Seminars in nuclear medicine; 2008: Elsevier.","DOI":"10.1053\/j.semnuclmed.2008.05.002"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105088_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225Actinium and 213Bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr. Radiopharm."},{"issue":"10459","key":"10.1016\/j.critrevonc.2025.105088_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105088_bib22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.critrevonc.2025.105088_bib23","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105088_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105088_bib25","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2967\/jnumed.123.266125","article-title":"177)Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer and prior (223)Ra (RALU study)","volume":"64","author":"Rahbar","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105088_bib26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2967\/jnumed.122.264456","article-title":"Safety and survival outcomes of (177)Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer with prior (223)Ra treatment: the RALU study","volume":"64","author":"Rahbar","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105088_bib27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105088_bib28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105088_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.121.262240","article-title":"177)Lu-prostate-specific membrane antigen ligand after (223)Ra treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience","volume":"63","author":"Sartor","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105088_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105088_bib31","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.7150\/thno.92273","article-title":"161)Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [(177)Lu]Lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105088_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10050946","article-title":"Total tumor volume on (18)F-PSMA-1007 PET as additional imaging biomarker in mCRPC patients undergoing PSMA-targeted alpha therapy with (225)Ac-PSMA-I&T","volume":"10","author":"Unterrainer","year":"2022","journal-title":"Biomedicines"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105088_bib33","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105088_bib34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-targeted \u03b1-therapy using (225)Ac-PSMA-I&T in advanced-mCRPC patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J. Nucl. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:28:32Z","timestamp":1770035312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"alternative-id":["S1040842825004767"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105088","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential use of targeted radioligand therapies in metastatic castration-resistant prostate cancer: A case report and systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105088"}}